Cystic Fibrosis-Pipeline Review, H1 2017

Cystic Fibrosis-Pipeline Review, H1 2017


  • Products Id :- GMDHC9218IDB
  • |
  • Pages: 383
  • |
  • |
  • |
  Request for Sample Report
  Request A Quote

Executive Summary

Cystic Fibrosis-Pipeline Review, H1 2017

Summary

Global Markets Direct's latest Pharmaceutical and Healthcare disease pipeline guide Cystic Fibrosis-Pipeline Review, H1 2017, provides an overview of the Cystic Fibrosis (Respiratory) pipeline landscape.

Cystic fibrosis (CF) is an inherited disease that causes mucus to build up and clog some of the body's organs, particularly the lungs and pancreas. Cystic fibrosis affects the cells that produce mucus, sweat and digestive juices. Symptoms include wheezing, breathlessness, repeated lung infections, inflamed nasal passages or a stuffy nose and severe constipation. Risk factors include family history and race (Northern European ancestry). Treatment includes antibiotics, mucus-thinning, bronchodilators and oral pancreatic enzymes.

Report Highlights

Global Markets Direct's Pharmaceutical and Healthcare latest pipeline guide Cystic Fibrosis-Pipeline Review, H1 2017, provides comprehensive information on the therapeutics under development for Cystic Fibrosis (Respiratory), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.

The Cystic Fibrosis (Respiratory) pipeline guide also reviews of key players involved in therapeutic development for Cystic Fibrosis and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies /Universities /Institutes, the molecules developed by Companies in Pre-Registration, Filing rejected/Withdrawn, Phase III, Phase II, Phase I, IND/CTA Filed, Preclinical, Discovery and Unknown stages are 1, 1, 5, 25, 27, 1, 55, 25 and 2 respectively. Similarly, the Universities portfolio in Phase II, Preclinical, Discovery and Unknown stages comprises 2, 4, 7 and 1 molecules, respectively.

Cystic Fibrosis (Respiratory) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from Global Markets Direct's proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

Note: Certain content / sections in the pipeline guide may be removed or altered based on the availability and relevance of data.

Scope

The pipeline guide provides a snapshot of the global therapeutic landscape of Cystic Fibrosis (Respiratory).

The pipeline guide reviews pipeline therapeutics for Cystic Fibrosis (Respiratory) by companies and universities/research institutes based on information derived from company and industry-specific sources.

The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.

The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.

The pipeline guide reviews key companies involved in Cystic Fibrosis (Respiratory) therapeutics and enlists all their major and minor projects.

The pipeline guide evaluates Cystic Fibrosis (Respiratory) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type.

The pipeline guide encapsulates all the dormant and discontinued pipeline projects.

The pipeline guide reviews latest news related to pipeline therapeutics for Cystic Fibrosis (Respiratory)

Reasons to buy

Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.

Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.

Find and recognize significant and varied types of therapeutics under development for Cystic Fibrosis (Respiratory).

Classify potential new clients or partners in the target demographic.

Develop tactical initiatives by understanding the focus areas of leading companies.

Plan mergers and acquisitions meritoriously by identifying key players and it's most promising pipeline therapeutics.

Formulate corrective measures for pipeline projects by understanding Cystic Fibrosis (Respiratory) pipeline depth and focus of Indication therapeutics.

Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.

Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.



Read More



Contact Us:
Ken Research
Ankur Gupta, Head Marketing & Communications

+91-9015378249

Table of Contents

Table of Contents 2

Introduction 5

Cystic Fibrosis-Overview 6

Cystic Fibrosis-Therapeutics Development 7

Cystic Fibrosis-Therapeutics Assessment 25

Cystic Fibrosis-Companies Involved in Therapeutics Development 37

Cystic Fibrosis-Drug Profiles 75

Cystic Fibrosis-Dormant Projects 348

Cystic Fibrosis-Discontinued Products 354

Cystic Fibrosis-Product Development Milestones 355

Appendix 370

List of Figures

Number of Products under Development for Cystic Fibrosis, H1 2017

Number of Products under Development by Companies, H1 2017

Number of Products under Development by Universities/Institutes, H1 2017

Number of Products by Top 10 Targets, H1 2017

Number of Products by Stage and Top 10 Targets, H1 2017

Number of Products by Top 10 Mechanism of Actions, H1 2017

Number of Products by Stage and Top 10 Mechanism of Actions, H1 2017

Number of Products by Routes of Administration, H1 2017

Number of Products by Stage and Routes of Administration, H1 2017

Number of Products by Top 10 Molecule Types, H1 2017

Number of Products by Stage and Top 10 Molecule Types, H1 2017

List of Tables

Number of Products under Development for Cystic Fibrosis, H1 2017

Number of Products under Development by Companies, H1 2017

Number of Products under Development by Companies, H1 2017 (Contd..1), H1 2017

Number of Products under Development by Companies, H1 2017 (Contd..2), H1 2017

Number of Products under Development by Companies, H1 2017 (Contd..3), H1 2017

Number of Products under Development by Companies, H1 2017 (Contd..4), H1 2017

Number of Products under Development by Companies, H1 2017 (Contd..5), H1 2017

Number of Products under Development by Universities/Institutes, H1 2017

Products under Development by Companies, H1 2017

Products under Development by Companies, H1 2017 (Contd..1), H1 2017

Products under Development by Companies, H1 2017 (Contd..2), H1 2017

Products under Development by Companies, H1 2017 (Contd..3), H1 2017

Products under Development by Companies, H1 2017 (Contd..4), H1 2017

Products under Development by Companies, H1 2017 (Contd..5), H1 2017

Products under Development by Companies, H1 2017 (Contd..6), H1 2017

Products under Development by Companies, H1 2017 (Contd..7), H1 2017

Products under Development by Universities/Institutes, H1 2017

Number of Products by Stage and Target, H1 2017

Number of Products by Stage and Target, H1 2017 (Contd..1), H1 2017

Number of Products by Stage and Target, H1 2017 (Contd..2), H1 2017

Number of Products by Stage and Mechanism of Action, H1 2017

Number of Products by Stage and Mechanism of Action, H1 2017 (Contd..1), H1 2017

Number of Products by Stage and Mechanism of Action, H1 2017 (Contd..2), H1 2017

Number of Products by Stage and Route of Administration, H1 2017

Number of Products by Stage and Molecule Type, H1 2017

Cystic Fibrosis-Pipeline by Achaogen Inc, H1 2017

Cystic Fibrosis-Pipeline by Actelion Ltd, H1 2017

Cystic Fibrosis-Pipeline by Advanced Inhalation Therapies (AIT) Ltd, H1 2017

Cystic Fibrosis-Pipeline by Aeolus Pharmaceuticals Inc, H1 2017

Cystic Fibrosis-Pipeline by Alaxia SAS, H1 2017

Cystic Fibrosis-Pipeline by AlgiPharma AS, H1 2017

Cystic Fibrosis-Pipeline by AmpliPhi Biosciences Corp, H1 2017

Cystic Fibrosis-Pipeline by Apteeus, H1 2017

Cystic Fibrosis-Pipeline by Arch Biopartners Inc, H1 2017

Cystic Fibrosis-Pipeline by Arcturus Therapeutics Inc, H1 2017

Cystic Fibrosis-Pipeline by Aridis Pharmaceuticals LLC, H1 2017

Cystic Fibrosis-Pipeline by AstraZeneca Plc, H1 2017

Cystic Fibrosis-Pipeline by Bayer AG, H1 2017

Cystic Fibrosis-Pipeline by Boehringer Ingelheim GmbH, H1 2017

Cystic Fibrosis-Pipeline by Catabasis Pharmaceuticals Inc, H1 2017

Cystic Fibrosis-Pipeline by Celtaxsys Inc, H1 2017

Cystic Fibrosis-Pipeline by Chiesi Farmaceutici SpA, H1 2017

Cystic Fibrosis-Pipeline by Cilian AG, H1 2017

Cystic Fibrosis-Pipeline by Concert Pharmaceuticals Inc, H1 2017

Cystic Fibrosis-Pipeline by CRISPR Therapeutics, H1 2017

Cystic Fibrosis-Pipeline by Cyclacel Pharmaceuticals Inc, H1 2017

Cystic Fibrosis-Pipeline by DiscoveryBiomed Inc, H1 2017

Cystic Fibrosis-Pipeline by Editas Medicine Inc, H1 2017

Cystic Fibrosis-Pipeline by Eloxx Pharmaceuticals Ltd, H1 2017

Cystic Fibrosis-Pipeline by Enterprise Therapeutics Ltd, H1 2017

Cystic Fibrosis-Pipeline by Errant Gene Therapeutics LLC, H1 2017

Cystic Fibrosis-Pipeline by ethris GmbH, H1 2017

Cystic Fibrosis-Pipeline by Galapagos NV, H1 2017

Cystic Fibrosis-Pipeline by Gilead Sciences Inc, H1 2017

Cystic Fibrosis-Pipeline by GlaxoSmithKline Plc, H1 2017

Cystic Fibrosis-Pipeline by Grifols SA, H1 2017

Cystic Fibrosis-Pipeline by Grupo Praxis Pharmaceutical SA, H1 2017

Cystic Fibrosis-Pipeline by Horizon Pharma Plc, H1 2017

Cystic Fibrosis-Pipeline by ID Pharma Co Ltd, H1 2017

Cystic Fibrosis-Pipeline by Immun System IMS AB, H1 2017

Cystic Fibrosis-Pipeline by Insmed Inc, H1 2017

Cystic Fibrosis-Pipeline by Invion Ltd, H1 2017

Cystic Fibrosis-Pipeline by Ionis Pharmaceuticals Inc, H1 2017

Cystic Fibrosis-Pipeline by JHL Biotech Inc, H1 2017

Cystic Fibrosis-Pipeline by Kamada Ltd, H1 2017

Cystic Fibrosis-Pipeline by Kyorin Pharmaceutical Co Ltd, H1 2017

Cystic Fibrosis-Pipeline by La Jolla Pharmaceutical Company, H1 2017

Cystic Fibrosis-Pipeline by Lakewood-Amedex Inc, H1 2017

Cystic Fibrosis-Pipeline by Lamellar Biomedical Ltd, H1 2017

Cystic Fibrosis-Pipeline by Laurent Pharmaceuticals Inc, H1 2017

Cystic Fibrosis-Pipeline by Lexicon Pharmaceuticals Inc, H1 2017

Cystic Fibrosis-Pipeline by Mast Therapeutics Inc, H1 2017

Cystic Fibrosis-Pipeline by Merck & Co Inc, H1 2017

Cystic Fibrosis-Pipeline by Microbion Corp, H1 2017

Cystic Fibrosis-Pipeline by Mucokinetica Ltd, H1 2017

Cystic Fibrosis-Pipeline by Novabiotics Ltd, H1 2017

Cystic Fibrosis-Pipeline by Novartis AG, H1 2017

Cystic Fibrosis-Pipeline by OSE Immunotherapeutics, H1 2017

Cystic Fibrosis-Pipeline by Paranta Biosciences Ltd, H1 2017

Cystic Fibrosis-Pipeline by Parion Sciences Inc, H1 2017

Cystic Fibrosis-Pipeline by Pfizer Inc, H1 2017

Cystic Fibrosis-Pipeline by Pharmaxis Ltd, H1 2017

Cystic Fibrosis-Pipeline by PhaseBio Pharmaceuticals Inc, H1 2017

Cystic Fibrosis-Pipeline by Polyphor Ltd, H1 2017

Cystic Fibrosis-Pipeline by Progenra Inc, H1 2017

Cystic Fibrosis-Pipeline by ProMetic Life Sciences Inc, H1 2017

Cystic Fibrosis-Pipeline by ProQR Therapeutics NV, H1 2017

Cystic Fibrosis-Pipeline by Protalix BioTherapeutics Inc, H1 2017

Cystic Fibrosis-Pipeline by Proteostasis Therapeutics Inc, H1 2017

Cystic Fibrosis-Pipeline by Pulmatrix Inc, H1 2017

Cystic Fibrosis-Pipeline by RaNA Therapeutics Inc, H1 2017

Cystic Fibrosis-Pipeline by ReveraGen BioPharma Inc, H1 2017

Cystic Fibrosis-Pipeline by Savara Inc, H1 2017

Cystic Fibrosis-Pipeline by Shionogi & Co Ltd, H1 2017

Cystic Fibrosis-Pipeline by SOM Biotech SL, H1 2017

Cystic Fibrosis-Pipeline by Synedgen Inc, H1 2017

Cystic Fibrosis-Pipeline by Synovo GmbH, H1 2017

Cystic Fibrosis-Pipeline by Vanda Pharmaceuticals Inc, H1 2017

Cystic Fibrosis-Pipeline by Verona Pharma Plc, H1 2017

Cystic Fibrosis-Pipeline by Vertex Pharmaceuticals Inc, H1 2017

Cystic Fibrosis-Pipeline by Xenetic Biosciences Inc, H1 2017

Cystic Fibrosis-Dormant Projects, H1 2017

Cystic Fibrosis-Dormant Projects, H1 2017 (Contd..1), H1 2017

Cystic Fibrosis-Dormant Projects, H1 2017 (Contd..2), H1 2017

Cystic Fibrosis-Dormant Projects, H1 2017 (Contd..3), H1 2017

Cystic Fibrosis-Dormant Projects, H1 2017 (Contd..4), H1 2017

Cystic Fibrosis-Dormant Projects, H1 2017 (Contd..5), H1 2017

Cystic Fibrosis-Discontinued Products, H1 2017

Single User License:
Report can be used by individual purchaser only

Site License:
Report can be shared by unlimited users within one corporate location, e.g. a regional office

Corporate User License:
Report can be shared globally by unlimited users within the purchasing corporation e.g. all employees of a single company

To know more information on Purchase by Section, please send a mail to query [@] kenresearch.com
 

Achaogen Inc, Actelion Ltd, Advanced Inhalation Therapies (AIT) Ltd, Aeolus Pharmaceuticals Inc, Alaxia SAS, AlgiPharma AS, AmpliPhi Biosciences Corp, Apteeus, Arch Biopartners Inc, Arcturus Therapeutics Inc, Aridis Pharmaceuticals LLC, AstraZeneca Plc, Bayer AG, Boehringer Ingelheim GmbH, Catabasis Pharmaceuticals Inc, Celtaxsys Inc, Chiesi Farmaceutici SpA, Cilian AG, Concert Pharmaceuticals Inc, CRISPR Therapeutics, Cyclacel Pharmaceuticals Inc, DiscoveryBiomed Inc, Editas Medicine Inc, Eloxx Pharmaceuticals Ltd, Enterprise Therapeutics Ltd, Errant Gene Therapeutics LLC, ethris GmbH, Galapagos NV, Gilead Sciences Inc, GlaxoSmithKline Plc, Grifols SA, Grupo Praxis Pharmaceutical SA, Horizon Pharma Plc, ID Pharma Co Ltd, Immun System IMS AB, Insmed Inc, Invion Ltd, Ionis Pharmaceuticals Inc, JHL Biotech Inc, Kamada Ltd, Kyorin Pharmaceutical Co Ltd, La Jolla Pharmaceutical Company, Lakewood-Amedex Inc, Lamellar Biomedical Ltd, Laurent Pharmaceuticals Inc, Lexicon Pharmaceuticals Inc, Mast Therapeutics Inc, Merck & Co Inc, Microbion Corp, Mucokinetica Ltd, Novabiotics Ltd, Novartis AG, OSE Immunotherapeutics, Paranta Biosciences Ltd, Parion Sciences Inc, Pfizer Inc, Pharmaxis Ltd, PhaseBio Pharmaceuticals Inc, Polyphor Ltd, Progenra Inc, ProMetic Life Sciences Inc, ProQR Therapeutics NV, Protalix BioTherapeutics Inc, Proteostasis Therapeutics Inc, Pulmatrix Inc, RaNA Therapeutics Inc, ReveraGen BioPharma Inc, Savara Inc, Shionogi & Co Ltd, SOM Biotech SL, Synedgen Inc, Synovo GmbH, Vanda Pharmaceuticals Inc, Verona Pharma Plc, Vertex Pharmaceuticals Inc, Xenetic Biosciences Inc

select a license

Single User License
USD 2000 INR 130100
Site License
USD 4000 INR 260200
Corporate User License
USD 6000 INR 390300

NEWSLETTER BY CATEGORY




Testimonials

The report sent to us was on the point, and its information was quite extensive, well structured, and well researched. More importantly what we valued was your response time and professionalism. As a leading global consulting firm, our clients expect high quality deliverables in short periods of time, so a reliable research partner is essential. For the price that you have charged the quality of your services were exceptional. We look forward to continue our relationship with your team on future engagements....

This is with regards to your report on India PVC pipes and fitting market outlook industry outlook to 2019. This is a very well written report and accept my compliments on the same.... ...

I am pleased to see the very useful and productive information in the report..Very well structured great presentation reflect professionalism in your research studies....

While we still are studying and analysing your reports about Vietnam & Thailand, we would like to convey to your research team that they have done a very good job in compiling so much of information together. We hope to see more of such well researched reports. All the best & keep it up. ...

We would like to appreciate Ken Research for their great efforts and wonderful support in providing the Market Intelligence Report for ITPC. The information, statistics and research are well understandable and very clear to the point. We are happy with Ken research for their good client service, on-time delivery of the report and as said the report itself. Thank you Ken research for bringing the valuable output for us. We would be looking forward to have more research with you in the near future. Wish you a success in your business!...



Related Products in vertical
Ken Research Pvt. Ltd. Unit 14, Tower B3, Spaze I Tech Business Park, Sohna Road, sector 49
     Gurgaon, Haryana - 122001, India

download

Company Brochure

Engage with Us

query [@] kenresearch.com